bilaterals.org logo
bilaterals.org logo

medicines


Unresolved trade pact: India to meet EU in Jan
Months after it called off talks between chief negotiators of the two sides on free trade agreement (FTA) to protest against the ban on sale of around 700 pharma products of a domestic company, India will meet officials from the European Union (EU) later next month to “take stock of the negotiations” on the long-pending FTA.
Big Pharma rewarded as drug prices keep soaring
The escalation in patent protections is set to occur just as drug prices hit all-time highs in Canada and pharmaceutical investment in research and development sinks to decade-long lows.
Lessons to learn from TPP: What the EU shouldn’t do in TTIP
Although TPP seems a remote issue, it could have a direct impact on EU consumers.
TPP strengthens controversial IP arbitration
While the agreement was being negotiated, the US Trade Representative stated that a much-criticized arbitration process included in the TPP would not apply to intellectual property. Turns out, it does apply to IP.
Pacific trade deal could limit affordable drugs: world health chief
A massive trade pact between 12 Pacific rim countries could limit the availability of affordable medicines, the head of the World Health Organization said
TPP on registration of drugs, bans requirements to disclose or consider certain financial or pricing data
There is a paucity of information on drug prices, revenues and other relative information on the economics of the pharmaceutical market.
TPP text shows some impacts from community campaigns, but still favours corporate rights over citizens and communities
Preliminary analysis of the thousands of pages of the main chapters of the TPP text show there are still devils in the detail on medicine monopolies, investor rights to sue governments and copyright monopolies.
Will the Trans Pacific Partnership have an impact on Indian pharma industry?
Implications of the TPP on the Indian pharma industry might not be entirely clear yet. But there is a need for India to engage in the debate of trade deals and public interest.
ATL MST Sida-Tunis tire la sonnette d’alarme : l’accès des Tunisiens aux médicaments en danger
Les conséquences des dispositions relatives à la propriété intellectuelle contenues dans l’accord signé entre l’Union Européenne et la Tunisie et leurs conséquences sur la santé publique en Tunisie inquiètent.
India must resist US pressure on generic drugs, African leaders to tell Modi
So far, the NDA government has been a mute spectator to the US pharma strategy of forcing Indian generics manufacturers to produce only what is required for Indian consumers and abandon the export of cheap drugs to Africa
USITC Report on India (#2) now available
The United States International Trade Commission (USITC) has published a report on IPR policy transparency by India’s new government
The problem with tying health care to trade
Writing pharmaceutical regulations into international trade deals can have costly consequences.
What the Trans-Pacific Partnership means for the cost of drugs
A quick analysis of the leaked text shows there are good reasons to be concerned that the TPP’s generous IP protections could still prove a minefield for efforts to control drug costs in Canada
Drugs row threatens health sector budget
Ahead of a meeting between Indian Prime Minister Modi and German Chancellor Merkel this week, European manufacturers had already protested India’s patents policy, arguing that it doesn’t protect sensitive technology.
Preliminary comments on the completed Trans Pacific Partnership (TPP) intellectual property chapter
The TPP’s intellectual property chapter represents nothing less than a disaster for global health. Many harmful provisions still remain in the final chapter, bearing out the concerns of public health advocates.
Doctors without borders blasts TPP’s impact on life-saving drugs
The TPP could give pharmaceutical corporations more power to control medicine markets and “impose higher prices for longer.”
Secret Trans - Pacific (TPP) deal lacks detail on medicines, includes corporate rights to sue governments
The lack of access to details in the text means governments can put a positive spin on the deal, but the devil is in the detail.
Trans-Pacific Partnership: ’50/50’ chance of trade deal today as negotiators lock horns over medical patent protection
Australia — along with others such as New Zealand and Chile — has been unwilling to offer more than five years protection for the medicines, because longer terms would increase the cost of state-subsidised medical programs.
U.S., Australia agree on complicated compromise on biologic drugs
Countries in the trade bloc would have an alternative of either providing eight years of exclusivity to biologic drugs, or providing five years of so-called data exclusivity plus up to three more years under a regulatory framework in the TPP.
US, Australia drug dispute is holding up settlement of the Trans Pacific trade deal
A standoff between Australia and the United States on monopoly rules for pharmaceutical drugs has emerged as the ultimate impediment to clinching an historic trade deal sweeping across 12 Pacific Rim countries.